Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Veracyte Inc | VCYT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 19.48 | 04:09:51 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 19.48 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 18.61 - 30.52 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 19.48 | USD |
Veracyte Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.46B | 75.07M | - | 361.05M | -74.4M | -0.99 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Veracyte News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VCYT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 19.11 | 20.70 | 19.02 | 19.64 | 746,878 | 0.37 | 1.94% |
| 1 Month | 22.09 | 22.10 | 18.61 | 20.00 | 650,562 | -2.61 | -11.82% |
| 3 Months | 24.72 | 26.59 | 18.61 | 22.12 | 686,163 | -5.24 | -21.20% |
| 6 Months | 20.13 | 29.35 | 18.61 | 23.86 | 651,018 | -0.65 | -3.23% |
| 1 Year | 22.10 | 30.52 | 18.61 | 24.36 | 621,030 | -2.62 | -11.86% |
| 3 Years | 50.30 | 54.13 | 14.85 | 27.40 | 748,387 | -30.82 | -61.27% |
| 5 Years | 23.00 | 86.03 | 13.90 | 30.68 | 699,751 | -3.52 | -15.30% |
Veracyte Description
| Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis product. |
